Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany.
Future Oncol. 2019 Aug;15(23):2687-2697. doi: 10.2217/fon-2019-0154. Epub 2019 Jun 11.
The Bruton's tyrosine kinase inhibitor ibrutinib represents a highly effective single substance in the treatment of Waldenström's macroglobulinemia. Ibrutinib monotherapy is a valid therapeutic option either in the relapsed or refractory setting or in patients first line, particulary when they are ineligible for chemotherapy. However, the treatment success depends on the genotype. Recent data suggest that ibrutinib in combination with rituximab may partially overcome this genotype dependency.
布鲁顿酪氨酸激酶抑制剂伊布替尼在治疗华氏巨球蛋白血症方面是一种非常有效的单一药物。伊布替尼单药治疗无论是在复发或难治性患者中，还是在一线患者中，特别是对于那些不适合化疗的患者，都是一种有效的治疗选择。然而，治疗的成功取决于基因型。最近的数据表明，伊布替尼联合利妥昔单抗可能部分克服这种基因型依赖性。
